Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

Verdict

Headline takes no side. We score ASMB +1.00 across four claims — strongly bullish.

Headline says

No call

No rating or direction in the headline

Expected · ASMB

+1.00strongly bullish

−1 bearish0bullish +1

More positive than 98% of ticker scores this week

What matters in this story